




Biased agonism in drug discovery – is it too soon to choose a path? 
 
 
Martin C. Michel, Steven J. Charlton 
 
Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany (MCM) 
Department of Life Sciences, University of Nottingham, Nottingham, UK (SJC) 







Running title: Biased agonism in drug discovery 
 
Address for correspondence: 
Prof. Martin C. Michel 
Dept. of Pharmacology 
Johannes Gutenberg University 
Obere Zahlbacher Str. 67 
55131 Mainz, Germany 
marmiche@uni-mainz.de  
 
Number of text pages: 13 
Number of tables: none 
Number of figures: 1 
Number of references: 83 
Number of words in Abstract: 194 
Number of words in Introduction: 1127 
Number of words in Discussion/Conclusions: 310 
 
Abbreviations:  
AT1R, angiotensin II type 1 receptor 
ERK, extracellular signal-regulated kinase 
GPCR, G protein-coupled receptor 
OAB, overactive bladder syndrome 
PTX, pertussis toxin 








A single receptor can activate multiple signaling pathways that have distinct or even opposite 
effects on cell function. Biased agonists stabilize receptor conformations preferentially 
stimulating one of these pathways and, therefore, allow a more targeted modulation of cell 
function and treatment of disease. Dedicated development of biased agonists has led to 
promising drug candidates in clinical development, such as the G protein-biased µ opioid 
receptor agonist oliceridine. However, leveraging the theoretic potential of biased agonism for 
drug discovery faces several challenges. Some of them are technical, such as techniques for 
quantitative analysis of bias and development of suitable screening assays. Others are more 
fundamental, such as the need to robustly identify in a very early phase which cell type 
harbors the cellular target of the drug candidate, which signaling pathway leads to the desired 
therapeutic effect and how these pathways may be modulated in the disease to be treated. We 
conclude that biased agonism has potential mainly in the treatment of conditions with a well-
understood pathophysiology; in contrast, it may increase effort and commercial risk under 
circumstances where the pathophysiology has been less well defined, as is the case with many 









It has been assumed historically that a given G protein-coupled receptor (GPCR) primarily 
couples to one G protein and signaling pathway, for instance angiotensin II type 1 receptors 
(AT1R), muscarinic M3 receptors and α1-adrenoceptors receptors to Gq, muscarinic M2 
receptors, µ opioid receptors and α2-adrenoceptors to Gi, and β-adrenoceptors to Gs  (Bylund 
et al., 1994; Caulfield and Birdsall, 1998; de Gasparo et al., 2000; Dhawan et al., 1996). 
While exceptions from this rule have been reported early after the definition and classification 
of G proteins, it only became accepted in the past decade that coupling of a single GPCR to 
multiple G proteins is the rule and not the exception. Receptors typically coupling to Gq 
proteins can also couple to Gi proteins, for instance AT1R (Crawford et al., 1992), or Gs 
proteins, for instance α1B-adrenoceptors (Horie et al., 1995). Conversely, typically Gi-coupled 
receptors such as M2 muscarinic acetylcholine receptors can also couple to Gq (Schmidt et al., 
1995) and typically Gs-coupled receptors such as β2- and β3-adrenoceptors to Gi (Cao et al., 
2000) and/or Gq (Wenzel-Seifert and Seifert, 2000). Moreover, GPCRs can directly couple 
not only to G proteins but also to other signaling molecules such as arrestins (Peterson and 
Luttrell, 2017) or src (Cao et al., 2000). Apparently, the ‘classic’ or ‘canonical’ signaling 
pathway of a receptor is present in most if not all cell types, whereas the additional or ‘non-
canonical’ signaling pathways can exhibit a more restricted presence. For instance, we have 
detected coupling to cAMP formation upon β-adrenoceptor stimulation, presumably via Gs, in 
every cell type we ever studied; in contrast, we only detected coupling to phosphorylation of 
extracellular signal-regulated kinase (ERK) via Gi in only some cell types. This does not 
necessarily mean that coupling to additional signaling pathways per se is restricted, but it may 






The term ‘biased agonism’, originally introduced by Jarpe (Jarpe et al., 1998), describes the 
phenomenon that a ligand preferentially activates one of several signaling pathways, whereas 
another agonist in the same system and acting on the same receptor preferentially activates 
another pathway (Patel et al., 2010). This phenomenon has also been referred to as ‘stimulus 
trafficking’ (Kenakin, 1995), ‘functional dissociation’ (Whistler et al., 1999), ‘biased 
inhibition’ (Kudlacek et al., 2002), ‘differential engagement’ (Manning, 2002), or ‘ligand-
directed signaling’ (Michel and Alewijnse, 2007). Such preferential coupling translates into 
differential induction of receptor trafficking and gene transcription programs (Delgado-Peraza 
et al., 2016; Maudsley et al., 2015). Of note, the concept of biased agonism is not necessarily 
restricted to GPCRs and could also be applied other signaling processes where the ligand-
activated molecule may bind to more than one other partner, for instance to steroid hormone 
receptors and other ligand-activated transcription factors (Michel et al., 2014). 
 
Perhaps the best-known hypothesis for the molecular basis of biased agonism relates to the 
fact that each ligand stabilizes a specific confirmation of a receptor (Costa-Neto et al., 2016; 
Kenakin and Miller, 2010; Kenakin and Morgan, 1989). This has been demonstrated using a 
variety of techniques, from NMR and DEER spectroscopy (Manglik et al., 2015) to 
stabilization of discrete conformations using allosteric nanobodies (Staus et al., 2016). As 
different receptor confirmations are likely to exhibit different affinities for various G proteins 
or G protein vs. arrestin, it appears logical that ligands inducing different receptor 
confirmations will also differentially affect coupling to specific G proteins, i.e. can exhibit 
biased agonism. Even minor chemical differences between ligands, e.g. their stereoisomers, 
may lead to preferential activation of distinct signaling pathways of the same receptor (Seifert 
and Dove, 2009). A structural basis for this is that distinct amino acids within a receptor are 






Many cases of proposed biased agonism include receptor binding to arrestins (Peterson and 
Luttrell, 2017), which in turn is often linked to activation of ERK (Delgado-Peraza et al., 
2016; Patel et al., 2010; Szakadati et al., 2015). Activation of ERK can also occur 
independent of arrestin, for instance via src (Cao et al., 2000). Moreover, it has been proposed 
that receptors primarily coupling to Gq or Gs proteins may activate ERK via Gi. An example 
of the latter are β3-adrenoceptors, which typically couple to Gs followed by activation of 
adenylyl cyclase and generation of cAMP but in some cell types can also cause (moderate) 
induction of ERK phosphorylation, which is proposed to involve activation of a pertussis 
toxin (PTX)-sensitive G protein, presumably Gi (Gerhardt et al., 1999; Soeder et al., 1999). 
However, the latter finding may not be robust, as it is based on the observation that less ERK 
phosphorylation was observed following pre-treatment with PTX, but the effects of PTX on 
basal ERK phosphorylation had not been assessed. Recent observation from our group 
confirm that PTX reduces ERK phosphorylation responses but also markedly lowers basal 
ERK phosphorylation; relative to this lowered basal value, β3-adrenoceptor ligands, if 
anything, yielded a greater relative enhancement of ERK phosphorylation than in the absence 
of PTX (Okeke et al., 2018). As this may also apply to other receptors, the true role of Gi 
proteins in ERK activation as alternative signaling pathway remains to be determined. Of 
note, ERK activation by Gq or Gs-coupled receptors may result from activation these G 
proteins (Lefkowitz et al., 2002).  
 
Based on the molecular basis of biased agonism, the specific signaling pathway activated by a 
ligand depends on several factors (Kenakin and Christopoulos, 2013). Firstly, the bimolecular 
interaction between ligand and receptor favors a specific receptor confirmation. This 
confirmation in turn will favor binding to a given G protein, arrestin or other signaling 
molecule. These two properties together define ligand bias (Kenakin, 2015b). Second, the 





degree they will be activated by a given receptor confirmation (Onfroy et al., 2017). Thus, 
high expression of one signaling partner may lead to preferential activation of this pathway 
even if the receptor confirmation has somewhat lower affinity for it. These stochiometric 
ratios define system bias (Kenakin, 2015b). Third, stochiometric ratios of G proteins and 
arrestins in given cell type or tissue can be modified by various physiological, pathological or 
iatrogenic factors. These effects define dynamic bias (Michel et al., 2014). Fourth, whether a 
given signaling pathway is stimulated by a ligand may be dominated by the intrinsic efficacy 
of that ligand for the pathway to be activated, which in turn depends on the relative affinity of 
the effector molecules for the receptor (Kenakin, 2015a). Of note, ligands may be weak partial 
agonists or even inverse agonists for one but strong agonists for another signaling pathway, 
for instance carvedilol at β2-adrenoceptors (Wisler et al., 2007) or L 748,337 at β3-
adrenoceptors (Sato et al., 2008). 
 
The promise of biased agonism 
 
As different G proteins and arrestins can modulate different signaling pathways, which in 
some cases may even have opposite effects on cell function, it is obvious that a ligand 
exhibiting biased agonism may yield distinct cellular responses as compared to a reference 
agonist. Some of these signaling responses may be desirable whereas others are undesirable, 
depending on the clinical condition under consideration. Thus, biased agonism in principle 
offers the possibility to selectively modulate one cellular/tissue response activated by a given 
receptor. For obvious reasons, this potential new avenue for selective modulation of cell and 
tissue function has generated considerable excitement. 
 
The most informative, but perhaps up to now only example how the potential of biased 





receptor agonists that exhibit analgesic effects but are associated with little constipation 
and/or respiratory suppression. Initial work had demonstrated that β-arrestin 2 knock-out mice 
or mice or rats injected with β-arrestin 2 interfering RNAs exhibited enhanced analgesia in 
response to opioid receptor agonists but less tolerance development and little constipation or 
respiratory suppression (Kelly, 2013; Raehal et al., 2011). This suggested that µ opioid 
receptor agonists biased for G protein activation but having little arrestin-mediated effects 
may exhibit a beneficial profile in the treatment of pain. Based on such findings, a team at 
Trevena has developed oliceridine (formerly known as TRV 130), a µ opioid receptor agonist 
(DeWire et al., 2013). Oliceridine exhibited robust G protein activation with a potency and 
efficacy similar to that of morphine, but caused far less arrestin recruitment and receptor 
internalization. It was a potent analgesic in mice and rats but caused less gastrointestinal 
dysfunction and respiratory suppression than morphine at equally analgesic doses. A clinical 
phase II study confirmed that oliceridine is a potent analgesic drug in patients (Viscusi et al., 
2016), and the FDA has granted breakthrough therapy status to this drug. Oliceridine 
produced similar analgesia as compared to morphine but caused fewer adverse events in a 
phase IIB study (Singla et al., 2017). However, presently available clinical data rely on short-
term administration, i.e. are unsuitable to determine whether the reduced desensitization, 
constipation and respiratory depression also occur with chronic treatment. In a different 
approach, other investigators have used the crystal structure of µ opioid receptors and docking 
studies with over 3 million molecules to identify another ligand with strong bias for the G 
protein as compared to arrestin pathways (Manglik et al., 2016) but the leading ligand 
identified in this study has not yet been tested clinically. Biased agonists have also been 
described for κ opioid receptors (White et al., 2014), but the relevance for this subtype in 
analgesia remains unclear. 
 






AT1R are modulators of many cardiovascular and renal functions, antagonists at these 
receptors have beneficial effects in corresponding disease and are clinically established drugs 
(Michel et al., 2016), but the clinically used AT1R antagonists do not exhibit biased agonism 
(Michel et al., 2013). However, experimental AT1R antagonists (Szakadati et al., 2015) and 
analogs of the endogenous agonist angiotensin II (Domazet et al., 2015) exhibit biased 
agonism. Therefore, investigators at Trevena also developed biased agonists at AT1R. They 
reasoned that the optimal ligand should be a potent antagonist for G protein activation via 
AT1R but a biased agonist promoting arrestin recruitment. Based on these consideration, they 
have identified TRV 027 (formerly known as TRV 120027), which inhibited angiotensin-
stimulated G protein signaling and stimulated arrestin recruitment and activated several kinase 
pathways, including ERK, src and endothelial NO synthase phosphorylation (Violin et al., 
2010). Similar to clinically used AT1R antagonists, TRV 027 reduced blood pressure but 
unlike the unbiased antagonists increased cardiac performance. This compound showed 
promising results in a dog model of congestive heart failure (Boerrigter et al., 2012) but a 
clinical phase II study (BLAST-AHF) failed to meet its composite primary endpoint 
consisting of (i) time from baseline to death through day 30, (ii) time from baseline to heart 
failure re-hospitalization through day 30, (iii) the first assessment time point following 
worsening heart failure through day 5, (iv) change in dyspnea visual analogue scale (VAS) 
score calculated as the area under the curve (AUC) representing the change from baseline 
over time from baseline through day 5, and (v) length of initial hospital stay (in days) from 
baseline (Pang et al., 2017). 
 
Many reasons may potentially explain why a novel drug fails to reach its primary endpoint in 
a clinical proof-of-concept study. However, it is noteworthy that the clinically most advanced 





mechanism of action that has been known for more than a century and numerous clinical and 
preclinical investigations have elaborated on the properties of morphine and how it decreases 
pain, causes tolerance and induces constipation and respiratory depression. Thus, the 
analgesic properties of opioid receptor agonists may be one of the best understood 
mechanisms in all of pharmacology. This is not likely to be the case for drug candidates that 
are based on novel targets. 
 
The challenge for drug discovery 
 
Two technical obstacles exist for leveraging the promise of biased agonism for drug 
discovery. Firstly, quantification of bias is not a trivial thing. Several useful approaches have 
been developed (Gundry et al., 2017; Kenakin, 2015a; Luttrell et al., 2015; Onaran et al., 
2017; Stott et al., 2016) with ΔΔlog(τ /KA) or ΔΔlog(Emax /EC50)  being perhaps the most 
useful tools currently available (Winpenny et al., 2016), but it has recently been demonstrated 
that the “kinetic context” at the level of ligand-receptor and receptor-pathway kinetics is also 
a key consideration which further complicates interpretation of data (Klein Herenbrink et al., 
2016; Lane et al., 2017). Identification of suitable screening assays for biased agonism, 
particularly high-throughput assays, is not trivial either, but there is theory to address this 
(Luttrell et al., 2015) and examples of practical implementation (McAnally et al., 2017; 
Winpenny et al., 2016). For reasons of scope, these obstacles will not be discussed further 
here. 
 
In our view, the biggest challenge for drug discovery based on biased agonism is establishing 
the correct target product profile (TPP), that is determining how effective the ligand to be 
developed should be for which signaling pathway. We illustrate this challenge largely based 





treatment of the overactive bladder syndrome (OAB) (Chapple et al., 2014; Ohlstein et al., 
2012). 
 
The signaling response to a receptor ligand depends on a combination of factors attributable 
to the ligand and the cell type/tissue in which it acts (ligand and system bias, respectively) 
(Kenakin, 2015b), and any changes this system may undergo in a pathological setting 
(dynamic bias) (Michel et al., 2014). Thus, the TPP of the lead compound for development 
must make assumptions which cell type harbors the molecular target responsible for desired 
and potential adverse effects, which signaling pathways mediate such effects and how this 
may be modulated in disease. Most β3-adrenoceptor agonists that have entered clinical 
development originally had been selected for the treatment of type 2 diabetes and obesity at a 
time when little knowledge was available about biased agonism and its implications; 
development for OAB was a repurposing endeavor (Michel and Korstanje, 2016). When 
repurposing studies for the OAB indication began, it had been assumed that the cellular target 
is the smooth muscle cell in the urinary bladder detrusor and that it mediates its desirable 
effects by increasing intracellular cAMP concentrations. Therefore, primary and secondary 
screens for suitable compounds in various companies were based on cAMP generation and 
relaxation of isolated detrusor strips in an organ bath, respectively, for instance for 
mirabegron (Takasu et al., 2007), ritobegron (Maruyama et al., 2012), solabegron (Hicks et 
al., 2007) or vibegron (Moyes et al., 2014). While one of these compounds has successfully 
undergone clinical development (Chapple et al., 2014), this may have been pure luck. Thus, 
while such drugs were already in clinical development, it became clear that cAMP generation 
plays a minor if any role in mediating detrusor smooth muscle relaxation by β-adrenoceptor 
agonists (Frazier et al., 2005; Uchida et al., 2005). Perhaps even more importantly, it is now 
increasingly being questioned whether the detrusor smooth muscle cell is indeed the cellular 





other structures (Michel, 2015). Therefore, even with today’s knowledge it is difficult to say 
which cell type (system bias) and which signaling pathway (ligand bias) would be the optimal 
target for the treatment of OAB.  
 
Moreover, β3-adrenoceptor ligands for the treatment of OAB must be agonists and based on 
their mode of action are assumed to provide symptom relief but not cure, indicating that long-
term treatment may be required. Desensitization is a general issue with extended treatment 
with GPCR agonists, and biased agonism may affect speed and extent of desensitization 
(Raehal et al., 2011), including those of β-adrenoceptors (Giminez et al., 2015). Therefore, it 
would be interesting to know whether the β3-adrenoceptor agonists used or intended for OAB 
treatment differ with regard to biased agonism and how this affects their susceptibility for 
desensitization. Whether any of the clinically tested β3-adrenoceptor agonists is a biased 
agonist remains unknown, but multiple experimental β3-adrenoceptor ligands are biased 
agonists (Evans et al., 2010). However, recent data show that both cAMP formation and ERK 
phosphorylation can undergo agonist-induced desensitization when expressed in Chinese 
hamster ovary cells, but that the pattern of desensitization differs between the two signaling 
pathways (Okeke et al., 2018). 
 
The above may sound a rather theoretical example since effective drugs have emerged. 
However, it illustrates how lack of pathophysiological knowledge increases risk in defining a 
TPP. If neither the cell type nor the signaling pathway leading to desired therapeutic effect is 
known with certainty, it remains a high-stakes gamble to define the desirable molecular 
properties of a drug development candidate, i.e. whether it should be a biased agonist and, if 
so, for which signaling pathway. Only early translational approaches (most likely based on 
animal models) will be able to test whether a TPP based on biased agonism is viable. 





do not address the validity of the inherent assumptions about validity of the model being used 
for the human target tissue and its alterations in disease. 
 
Animal models still play a key role in target validation activities for many disease states, 
particularly through the widespread use of knock-out mouse models. It is not common, 
however, for the degree of agonist bias to be studied at different species orthologs of the 
human receptor. The often-tacit assumption that the pathway bias of a particular compound is 
maintained in other species presents another potential risk when ascribing the required degree 
of bias for a particular disease. This can be exemplified by studies on the histamine H4 
receptor. JNJ7777120 was the first selective histamine H4 antagonist described and has been 
critical in defining a role for the H4 receptor in a variety of allergic and inflammatory 
processes (Thurmond et al., 2008). In 2011, however, it was discovered that although 
JNJ7777120 was an antagonist/inverse agonist at the human H4 receptor-mediated Gαi 
pathway, it was a partial agonist for the recruitment of β-arrestin to the human H4 receptor 
(Rosethorne and Charlton, 2011). Furthermore, it was able to induce a prolonged ERK 
activation. While this unexpected biased agonism at the human receptor clearly complicates 
the interpretation of previous studies that assumed pure antagonism, the waters were muddied 
further when the activity of JNJ7777120 was tested in a number of species orthologs of the H4 
receptor. Surprisingly, and in stark contrast to the human receptor, JNJ7777120 was a partial 
agonist at the Gαi pathway from the mouse, rat and dog H4 receptor (Schnell et al., 2011). This 
suggests that the beneficial effects of JNJ7777120 in the mouse (Thurmond et al., 2004) may 
be via H4-mediated Gαi activation, rather than inhibition, potentially leading to the wrong 
choice of pathway for treating human disease. These species differences also raise concerns 
over interpretation of safety studies that often utilize the rat and dog as preferred species for 





allostery and allosteric effects being species-dependent, it should not be surprising that biased 
agonism observed in one species does not necessarily translate to others. 
 
System bias, i.e. the stochiometric ratios between relevant signaling molecules, and dynamic 
bias, i.e. their possible alterations in disease and/or with treatment, are key in establishing the 
optimal TPP.  As indicated above, the signaling pathway being activated by a ligand depends 
on its intrinsic properties (ligand bias) and those of the cell type which is targeted (system 
bias). A key element that influences system bias is the stochiometric ratio of the different 
signaling molecules that are able to bind to activated receptor conformations (Onfroy et al., 
2017), which is likely to differ considerably between cell types and tissues. To highlight this 
point, we have analyzed data on mRNA expression of several thousand genes across a panel 
of 31 human tissues (Uhlen et al., 2015). This analysis shows that the ratio between 
expression of Gs, Gi and arrestin is highly variable between tissues (Figure 1). While these 
data are based on mRNA expression and we do not know how this translates into functional 
protein in those tissues, it is safe to assume that a similar lack of correlation will hold true at 
the protein level and also when cell types rather than tissues are analyzed. Moreover, if 
differential expression of these three elements exists across human tissues, it is likely that 
similar differential expression exists in animal models as compared to patients. 
 
To further complicate matters, expression of these various signaling components within a 
given cell type of tissue can be modulated by disease. For instance, congestive heart failure 
(the condition in which TRV 027 did not meet its primary endpoint) is characterized by a 
desensitization and down-regulation of β1-adrenoceptors (with less if any of β2-
adrenoceptors), down-regulation of Gs, and up-regulation of Gi, β-arrestin-1 and G-protein-





important in healthy tissue may be less or more prominent in disease tissue. We have 




While it is clear that correctly assigning the required bias for a new receptor is currently very 
difficult, there are several technological advances that promise to shed more light on the 
discrete signaling pathways activated in disease. In particular, novel imaging approaches to 
dissect individual pathways in living cells, tissues and animals will allow better matching of 
the kinetics and signal strength to a particular phenotypic response. FRET-based imaging 
biosensors have been developed that can monitor the spatiotemporal characteristics of 
signaling pathways (e.g. calcium, cAMP, phosphorylated ERK) in single cells and even 
subcellular compartments (Halls et al., 2015; Lohse et al., 2012). More exciting still is the 
recent use of genetically encoded versions of these sensors to measure spatiotemporal 
signaling at a whole organ level in living animals (Jones-Tabah et al., 2017; van Unen et al., 
2015). Using a microendoscopic implant, signaling via PKA and ERK1/2 has been imaged in 
the striatum of mice undergoing behavioral testing (Goto et al., 2015; Yamaguchi et al., 
2015), representing a step-change in our ability to monitor therapeutically relevant signaling 
pathways in their physiological context.  
 
The concomitant coupling of a single receptor to multiple signaling pathways and the 
selectivity for one of them that can theoretically be achieved by biased agonists is an 
attractive concept for drug discovery. However, definition of a sound TPP requires a lot of 
assumptions on system bias and dynamic bias, most importantly the cell type mediating the 
desired response and adverse responses, the signaling pathway causing them and how they 





for highly innovative targets at the time lead identification and optimization takes place, we 
feel that targeted development of biased agonists will be limited to a rather small number of 
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LEGENDS TO THE FIGURES 
 
Figure 1: Comparison of relative mRNA expression in a panel of 31 human tissues for Gs 
(GNAS), Gi2 (GNAI2) and β-arrestin (ARRB2). All data expressed in FKPM and means of 2-
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